179 related articles for article (PubMed ID: 21965747)
21. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
22. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
23. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
Gritzapis AD; Fridman A; Perez SA; La Monica N; Papamichail M; Aurisicchio L; Baxevanis CN
Vaccine; 2009 Dec; 28(1):162-70. PubMed ID: 19799847
[TBL] [Abstract][Full Text] [Related]
25. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
[TBL] [Abstract][Full Text] [Related]
26. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
27. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
28. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
29. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
30. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
31. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
32. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
33. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
34. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
[TBL] [Abstract][Full Text] [Related]
35. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Clin Immunol; 2005 Mar; 114(3):307-19. PubMed ID: 15721842
[TBL] [Abstract][Full Text] [Related]
36. The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen.
Hess AD; Thoburn C; Chen W; Miura Y; Van der Wall E
Clin Immunol; 2001 Oct; 101(1):67-76. PubMed ID: 11580228
[TBL] [Abstract][Full Text] [Related]
37. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
[TBL] [Abstract][Full Text] [Related]
38. Identification of B cell epitopes of dengue virus 2 NS3 protein by monoclonal antibody.
Tian Y; Chen W; Yang Y; Xu X; Zhang J; Wang J; Xiao L; Chen Z
Appl Microbiol Biotechnol; 2013 Feb; 97(4):1553-60. PubMed ID: 23081772
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.
Kono K; Takahashi A; Sugai H; Fujii H; Choudhury AR; Kiessling R; Matsumoto Y
Clin Cancer Res; 2002 Nov; 8(11):3394-400. PubMed ID: 12429626
[TBL] [Abstract][Full Text] [Related]
40. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]